Your session is about to expire
← Back to Search
Rifaximin for Encephalopathy
Study Summary
This trial will study the safety of Rifaximin, a drug used to treat hepatic encephalopathy, in subjects with severe liver impairment.
- Liver Encephalopathy
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 222 Patients • NCT01842581Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a long-term breathing problem that makes it difficult to get enough air.You have blockage in your intestines or suffer from inflammatory bowel disease.You have experienced bleeding from your digestive system within the past three months or are currently experiencing it.
- Group 1: Placebo
- Group 2: Rifaximin
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there a precedent of research involving Rifaximin?
"Rifaximin was first investigated in 2009 at the New mexico VA Healthcare System, and since then has seen 18,374 completed trials. At present there are 23 separate active studies being conducted primarily from La Jolla, California."
Are there any vacancies remaining in this clinical trial?
"Affirmative. The clinical trial data hosted on clinicialtrials.gov attests to the fact that this medical research has been actively recruiting since it was first posted in April 2013, and most recently updated in September 2022. 100 participants need to be enrolled from 23 separate sites."
How extensively has this clinical trial been disseminated across the state?
"At the moment, 23 trial sites are recruiting patients for this clinical study. These locations include La Jolla, Chicago and Rialto as well as 20 other spots across the country. To make participation easier on you, it is wise to pick a location proximate to your home in order to reduce any transportation costs that may arise."
What is the total enrollment capacity of this trial?
"Affirmative. According to clinicaltrials.gov, the study that was initially published on April 3rd 2013 is presently seeking participants. One hundred individuals must be recruited across 23 medical facilities for this trial to move forward."
What ailments is Rifaximin prescribed for?
"Rifaximin is usually utilized to treat recurrences of clostridium difficile infections. Additionally, it can be prescribed for bacterial infections, diarrhea and irritable bowel syndrome (IBS)."
Are there any adverse effects associated with using Rifaximin?
"Prior studies have indicated that Rifaximin is safe, so the Power team gave it a 3 out of 3 rating. This drug has already been approved for consumer use by relevant regulatory bodies."
Share this study with friends
Copy Link
Messenger